Vimarsana
Biggest News Aggregation in the World

Page 44 - Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Solid Tumors Today - Breaking & Trending Today

Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor -October 23, 2023 at 07:22 am EDT - Vimarsana News

Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor -October 23, 2023 at 07:22 am EDT

Published: October 23, 2023

News Release Media Contacts: Suzanne Frost +1 416-317-0304 Brian Kenney +1 215-620-0111 ...

Source: marketscreener.com
Related Topics:
United KingdomJames Wf CattoIndianj UrolClin UrolObrian KenneyKiran PatelJnjinnovmedand JanssenExchange CommissionDrug AdministrationClinical DevelopmentCompanies Of JohnsonEuropean Society For Medical OncologyDepartment Of OncologyEuropean Society For Medical Oncology CongressNone Of Janssen Research DevelopmentJanssen Research DevelopmentAstex PharmaceuticalsUs Food Drug AdministrationUniversity Of SheffieldJanssen Biotech IncJanssen Pharmaceutical Companies Of JohnsonNews ReleaseShow Improved RatesRecurrence Free SurvivalHigh Risknon Muscle Invasive Bladder Cancer
Landmark Phase 3 MARIPOSA Study Shows - Vimarsana News

Landmark Phase 3 MARIPOSA Study Shows

Published: October 23, 2023

Early data show an overall survival trend favoring the combination of amivantamab and lazertinib compared to osimertinib; consistent results seen in...

Source: globenewswire.com
Related Topics:
South KoreaUnited StatesSoult UkpyolsiRegion FlamandeRepublic Of KoreaJannsen Cilag GmbJanssen Cilag GmbByoung Chul ChoEuropean Society For Medical OncologyAmerican Lung AssociationEuropean UnionJanssen Research DevelopmentYuhan CorporationJanssen Biotech IncYonsei University College Of MedicineNational Cancer InstituteExchange Commission CopiesCompanies Of JohnsonJanssen ResearchEuropean CommissionJanssen Pharmaceutical Companies Of JohnsonNone Of The Janssen Pharmaceutical CompaniesEuropean Medicines AgencyPresidential SymposiumJanssen Pharmaceutical Companies
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer - Vimarsana News

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Published: October 22, 2023

KEYTRUDA plus enfortumab vedotin significantly prolonged overall survival by 53% - an improvement in median OS of more than 15 months - compared to chemotherapy in the total patient...

Source: marketscreener.com
Related Topics:
United StatesSeagen PadcevMerck Co IncSeagen IncAgensys IncStatement Of Merck Co IncExchange CommissionResponse Evaluation CriteriaSolid TumorsBacillus Calmette GuerinSelected Important SafetyImportant Safety InformationFatal Immune Mediated AdverseWhich Can Present With DiabeticNervous SystemConnective TissuePatients With MultipleNeck Squamous CellMismatch Repair DeficientMismatch Repair Deficient ColorectalLooking StatementSecurities Litigation Reform ActAnnual Report
Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with BALVERSA® (erdafitinib) Versus Chemotherapy - Vimarsana News

Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with BALVERSA® (erdafitinib) Versus Chemotherapy

Published: October 21, 2023

Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy MADRID, Oct. 21, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 2 randomized, open-label THOR-2 study evaluating BALVERSA® versus investigator […]

Source: bubblear.com
Related Topics:
United KingdomClin UrolObrian KenneyIndianj UrolKiran PatelJames Wf CattoJanssen Research DevelopmentJanssen Biotech IncUniversity Of SheffieldEuropean Society For Medical Oncology CongressNone Of Janssen Research DevelopmentEuropean Society For Medical OncologyAstex PharmaceuticalsClinical DevelopmentCompanies Of JohnsonExchange CommissionDrug AdministrationJanssen Pharmaceutical Companies Of JohnsonDepartment Of OncologyUs Food Drug AdministrationJanssen Pharmaceutical CompaniesBacillus Calmette GuProffered Paper Late Breaking SessionEuropean SocietyMedical Oncology
Results from Phase 2 THOR-2 Study Showed Improved Rates of - Vimarsana News

Results from Phase 2 THOR-2 Study Showed Improved Rates of

Published: October 21, 2023

Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical...

Source: globenewswire.com
Related Topics:
Region FlamandeUnited KingdomJanssen Cilag GmbIndianj UrolKiran PatelJames Wf CattoMartin VogelJanssen PharmaceuticaAstex Announces New Drug Discovery AllianceUniversity Of SheffieldClinical DevelopmentJanssen ResearchNone Of The Janssen Pharmaceutical CompaniesExchange CommissionJanssen Pharmaceutical CompaniesDrug AdministrationJanssen Pharmaceutical Companies Of JohnsonAstex TherapeuticsDepartment Of OncologyCompanies Of JohnsonEuropean Medicine AgencyEuropean Medicines AgencyUrology Care FoundationJanssen Research DevelopmentEuropean Society For Medical Oncology